Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 289, Issue 1 52-1, 2005, Pages

  Resta Lenert, Silvia ^a,b   Smitham, Jane ^a   Barrett, Kim E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Animal models; Barrier function; Gender differences

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FEMALE; HISTOPATHOLOGY; INTESTINE MUCOSA PERMEABILITY; ION TRANSPORT; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SURVIVAL RATE; TIGHT JUNCTION; WEIGHT REDUCTION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TRANSLOCATION; COLITIS; DIARRHEA; DISEASE MODELS, ANIMAL; FEMALE; HOUSING, ANIMAL; INTESTINAL MUCOSA; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PHENOTYPE; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; TIGHT JUNCTIONS;

EID: 21744441440     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00395.2004     Document Type: Article

References (29)

1. Bhan AK, Mizoguchi E, Smith RN, and Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 169: 195-207, 1999.
2. Boismenu R and Chen Y. Insights from mouse models of colitis. J Leukoc Biol 67: 267-278, 2000.
3. Bouma G and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533, 2003.
4. Elson CO and Cong Y. Understanding immune-microbial homeostasis in intestine. Immunol Res 26: 87-94, 2002.
5. Farrell RJ and Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178: 339-346, 2003.
6. Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 181-182: 299-303, 2002.
7. Gewirtz AT, Neish AS, and Madara JL. Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins. Adv Exp Med Biol 507: 229-236, 2002.
8. Guarner F, Casellas F, Borruel N, Antolin M, Videla S, Vilaseca J, and Malagelada JR. Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr 56, Suppl 4: S34-S8, 2002.
9. Heller F and Duchmann R. Intestinal flora and mucosal immune responses. Int J Med Microbiol 293: 77-86, 2003.
10. Hendrickson BA, Gokhale R, and Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15: 79-94, 2002.
11. Hibi T, Ogata H, and Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol 37: 409-417, 2002.
12. Ho GT, Moodie FM, and Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766, 2003.
13. Iizasa H, Genda N, Kitano T, Tomita M, Nishihara K, Hayashi M, Nakamura K, Kobayashi S, and Nakashima E. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J Pharm Sci 92: 569-576, 2003.
14. Kiernan JA. Hisiological and Histochemical Methods. Theory and Practice. London: Arnold, 1999.
15. Meddings JB. Intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 11: 47-53, 1997.
16. -/-) mice. Am J Pathol 160: 739-751, 2002.
17. Pallone F, Blanco Gdel V, Vavassori P, Monteleone I, Fina D, and Monteleone G. Genetic and pathogenetic insights into inflammatory bowel disease. Curr Gastroenterol Rep 5: 487-492, 2003.
18. Panwala CM, Jones JC, and Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drag resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161: 5733-5744, 1998.
19. Pizarro TT, Arseneau KO, Bamias G, and Cominelli F. Mouse models for the study of Crohn's disease. Trends Mol Med 9: 218-222, 2003.
20. Resta-Lenert S and Barrett K. Infection with enteroinvasive bacteria alters barrier function and transport properties of human intestinal epithelial cells: role of iNOS and COX-2 expression. Gastroenterology 122: 1070-1087, 2002.
21. Resta-Lenert S and Barrett K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive E. coli (EIEC). Gut 52: 988-997, 2003.
22. -/- mice (Abstract). Gastroenterology 124: A-672, 2003.
23. Saclarides TJ, Jakate SM, Coon JS, Bhattacharyya AK, Dominguez JM, Szeluga DJ, and Weinstein RS. Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis. Dis Colon Rectum 35: 747-752, 1992.
24. Sandborn WJ and Faubion WA. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep 2: 440-445, 2000.
25. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, and Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33, 2003.
26. Stadnicki A and Colman RW. Experimental models of inflammatory bowel disease. Arch Immunol Exp Ther 51: 149-155, 2003.
27. Strober W, Fuss IJ, Nakamura K, and Kitani A. Recent advances in the understanding of the induction and regulation of mucosal inflammation. J Gastroenterol 38: 55-58, 2003.
28. Ten Hove T, Drillenburg P, Wijnholds J, Te Velde AA, and van Deventer SJ. Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig Dis Sci 47: 2056-2063, 2002.
29. Yacyshyn B, Maksymowych W, and Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 60: 677-687, 1999.